Medtronic (MDT) Reports In-Line Q2 EPS; Updates on FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Medtronic (MDT) PT Raised to $83 at Piper Jaffray Following Q2 and Deal Progress
November 19, 2014 8:45 AM ESTPiper Jaffray analyst Brooks West reiterated an Overweight rating and boosted his price target on Medtronic, Inc. (NYSE: MDT) to $83.00 (from $74.00) Wednesday following solid Q2 results and progress on the Covidien deal.
West commented, "
Medtronic reported F2Q15 results with revenues of $4.366B... More
